NZ756264A - Treatment of brain cancer - Google Patents
Treatment of brain cancerInfo
- Publication number
- NZ756264A NZ756264A NZ756264A NZ75626413A NZ756264A NZ 756264 A NZ756264 A NZ 756264A NZ 756264 A NZ756264 A NZ 756264A NZ 75626413 A NZ75626413 A NZ 75626413A NZ 756264 A NZ756264 A NZ 756264A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- brain cancer
- dihydrooxazol
- triazolo
- yloxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615082P | 2012-03-23 | 2012-03-23 | |
| NZ74161513A NZ741615A (en) | 2012-03-23 | 2013-03-25 | Treatment of brain cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ756264A true NZ756264A (en) | 2022-09-30 |
Family
ID=48048296
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ756264A NZ756264A (en) | 2012-03-23 | 2013-03-25 | Treatment of brain cancer |
| NZ630843A NZ630843A (en) | 2012-03-23 | 2013-03-25 | Treatment of brain cancer |
| NZ724544A NZ724544A (en) | 2012-03-23 | 2013-03-25 | Treatment of brain cancer |
| NZ74161513A NZ741615A (en) | 2012-03-23 | 2013-03-25 | Treatment of brain cancer |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ630843A NZ630843A (en) | 2012-03-23 | 2013-03-25 | Treatment of brain cancer |
| NZ724544A NZ724544A (en) | 2012-03-23 | 2013-03-25 | Treatment of brain cancer |
| NZ74161513A NZ741615A (en) | 2012-03-23 | 2013-03-25 | Treatment of brain cancer |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20150110780A1 (https=) |
| EP (4) | EP3400943B1 (https=) |
| JP (6) | JP2015514075A (https=) |
| KR (3) | KR102317166B1 (https=) |
| CN (2) | CN109223791A (https=) |
| AU (4) | AU2013234921A1 (https=) |
| CA (1) | CA2867723C (https=) |
| CL (1) | CL2014002497A1 (https=) |
| CO (1) | CO7071139A2 (https=) |
| CY (2) | CY1120204T1 (https=) |
| DK (2) | DK3400943T3 (https=) |
| ES (2) | ES2855142T3 (https=) |
| HR (1) | HRP20180659T1 (https=) |
| HU (2) | HUE037966T2 (https=) |
| IL (3) | IL234627B (https=) |
| LT (1) | LT2827900T (https=) |
| MX (1) | MX354024B (https=) |
| MY (2) | MY202114A (https=) |
| NZ (4) | NZ756264A (https=) |
| PH (2) | PH12021550360A1 (https=) |
| PL (2) | PL3400943T3 (https=) |
| PT (2) | PT3400943T (https=) |
| RS (1) | RS57140B1 (https=) |
| RU (2) | RU2018138976A (https=) |
| SG (1) | SG11201405954YA (https=) |
| SI (2) | SI2827900T1 (https=) |
| SM (1) | SMT201800251T1 (https=) |
| TR (1) | TR201808450T4 (https=) |
| UA (1) | UA122044C2 (https=) |
| WO (1) | WO2013142875A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012323890A1 (en) | 2011-10-14 | 2014-05-29 | Array Biopharma Inc. | Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them |
| WO2013056108A2 (en) | 2011-10-14 | 2013-04-18 | Array Biopharma Inc. | Solid dispersion |
| EP3400943B1 (en) | 2012-03-23 | 2020-12-02 | Array Biopharma, Inc. | Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer |
| WO2018165015A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
| BR112019022280A2 (pt) | 2017-04-28 | 2020-05-19 | Seattle Genetics Inc | tratamento de cânceres de her2 positivo |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| CN118416236A (zh) | 2018-01-31 | 2024-08-02 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| JP7139448B2 (ja) * | 2018-04-09 | 2022-09-20 | ノボキュア ゲーエムベーハー | ＴＴＦｉｅｌｄｓ及びオーロラキナーゼ阻害剤による腫瘍の治療 |
| CN109942576B (zh) * | 2019-03-07 | 2020-09-11 | 上海工程技术大学 | Irbinitinib及中间体的制备方法 |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| CN111825604A (zh) * | 2019-04-16 | 2020-10-27 | 宁波药腾医药科技有限公司 | 一种图卡替尼及其中间产物的合成方法 |
| EP4013412B1 (en) | 2019-08-12 | 2026-01-28 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| MX2022008103A (es) * | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. |
| EP4084779B1 (en) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH690163A5 (fr) * | 1995-07-28 | 2000-05-31 | Symphar Sa | Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers. |
| US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| RU2255765C2 (ru) * | 2000-01-21 | 2005-07-10 | Чилдренз Хоспитал Лос-Анджелес | Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов |
| WO2001091794A2 (en) | 2000-05-30 | 2001-12-06 | Virginia Commonwealth University | Vitamin d3 analogs as radiosensitizers for the treatment of cancer |
| DK1660090T3 (da) | 2003-08-14 | 2012-12-17 | Array Biopharma Inc | Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer |
| JP2008501690A (ja) | 2004-06-03 | 2008-01-24 | スミスクライン ビーチャム （コーク） リミテッド | がんの治療方法 |
| CN1989112A (zh) * | 2004-06-03 | 2007-06-27 | 史密丝克莱恩比彻姆（科克）有限公司 | 癌症治疗方法 |
| ATE446294T1 (de) * | 2005-11-15 | 2009-11-15 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| BRPI0706788A2 (pt) | 2006-01-31 | 2011-04-05 | Novartis Ag | anticorpos antagonistas il-17 |
| WO2009042618A1 (en) * | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
| DK2644194T3 (en) * | 2008-03-18 | 2017-07-03 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| WO2013056108A2 (en) * | 2011-10-14 | 2013-04-18 | Array Biopharma Inc. | Solid dispersion |
| AU2012323890A1 (en) * | 2011-10-14 | 2014-05-29 | Array Biopharma Inc. | Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them |
| EP3400943B1 (en) | 2012-03-23 | 2020-12-02 | Array Biopharma, Inc. | Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer |
-
2013
- 2013-03-25 EP EP18162971.8A patent/EP3400943B1/en not_active Revoked
- 2013-03-25 CN CN201811150918.9A patent/CN109223791A/zh active Pending
- 2013-03-25 KR KR1020207027176A patent/KR102317166B1/ko active Active
- 2013-03-25 ES ES18162971T patent/ES2855142T3/es active Active
- 2013-03-25 NZ NZ756264A patent/NZ756264A/en unknown
- 2013-03-25 DK DK18162971.8T patent/DK3400943T3/da active
- 2013-03-25 US US14/387,533 patent/US20150110780A1/en not_active Abandoned
- 2013-03-25 EP EP23163332.2A patent/EP4252855A3/en not_active Withdrawn
- 2013-03-25 LT LTEP13714497.8T patent/LT2827900T/lt unknown
- 2013-03-25 SI SI201331019T patent/SI2827900T1/en unknown
- 2013-03-25 PT PT181629718T patent/PT3400943T/pt unknown
- 2013-03-25 ES ES13714497.8T patent/ES2673165T3/es active Active
- 2013-03-25 DK DK13714497.8T patent/DK2827900T3/en active
- 2013-03-25 RU RU2018138976A patent/RU2018138976A/ru unknown
- 2013-03-25 MY MYPI2019003395A patent/MY202114A/en unknown
- 2013-03-25 EP EP13714497.8A patent/EP2827900B1/en active Active
- 2013-03-25 PL PL18162971T patent/PL3400943T3/pl unknown
- 2013-03-25 KR KR1020147029340A patent/KR102160462B1/ko active Active
- 2013-03-25 PH PH1/2021/550360A patent/PH12021550360A1/en unknown
- 2013-03-25 JP JP2015501952A patent/JP2015514075A/ja active Pending
- 2013-03-25 AU AU2013234921A patent/AU2013234921A1/en not_active Abandoned
- 2013-03-25 TR TR2018/08450T patent/TR201808450T4/tr unknown
- 2013-03-25 WO PCT/US2013/033751 patent/WO2013142875A1/en not_active Ceased
- 2013-03-25 MX MX2014011437A patent/MX354024B/es active IP Right Grant
- 2013-03-25 SI SI201331844T patent/SI3400943T1/sl unknown
- 2013-03-25 SM SM20180251T patent/SMT201800251T1/it unknown
- 2013-03-25 SG SG11201405954YA patent/SG11201405954YA/en unknown
- 2013-03-25 NZ NZ630843A patent/NZ630843A/en unknown
- 2013-03-25 HU HUE13714497A patent/HUE037966T2/hu unknown
- 2013-03-25 RU RU2014142700A patent/RU2672575C2/ru active
- 2013-03-25 KR KR1020217033686A patent/KR102490961B1/ko active Active
- 2013-03-25 PT PT137144978T patent/PT2827900T/pt unknown
- 2013-03-25 PL PL13714497T patent/PL2827900T3/pl unknown
- 2013-03-25 CN CN201380015856.XA patent/CN104203279B/zh active Active
- 2013-03-25 HU HUE18162971A patent/HUE053156T2/hu unknown
- 2013-03-25 EP EP20210661.3A patent/EP3842044A1/en not_active Withdrawn
- 2013-03-25 HR HRP20180659TT patent/HRP20180659T1/hr unknown
- 2013-03-25 NZ NZ724544A patent/NZ724544A/en unknown
- 2013-03-25 CA CA2867723A patent/CA2867723C/en active Active
- 2013-03-25 NZ NZ74161513A patent/NZ741615A/en unknown
- 2013-03-25 MY MYPI2014702686A patent/MY174883A/en unknown
- 2013-03-25 RS RS20180484A patent/RS57140B1/sr unknown
- 2013-03-25 UA UAA201411479A patent/UA122044C2/uk unknown
-
2014
- 2014-09-12 PH PH12014502032A patent/PH12014502032A1/en unknown
- 2014-09-14 IL IL234627A patent/IL234627B/en active IP Right Grant
- 2014-09-19 CO CO14208829A patent/CO7071139A2/es unknown
- 2014-09-22 CL CL2014002497A patent/CL2014002497A1/es unknown
-
2017
- 2017-05-25 JP JP2017103957A patent/JP2017141302A/ja active Pending
- 2017-12-06 AU AU2017272232A patent/AU2017272232C1/en active Active
-
2018
- 2018-05-14 CY CY20181100493T patent/CY1120204T1/el unknown
- 2018-09-06 IL IL261659A patent/IL261659A/en unknown
-
2019
- 2019-02-27 JP JP2019034250A patent/JP6898960B2/ja active Active
- 2019-05-02 US US16/402,068 patent/US11504370B2/en active Active
- 2019-05-23 AU AU2019203618A patent/AU2019203618B2/en active Active
- 2019-09-09 IL IL269205A patent/IL269205B/en active IP Right Grant
-
2021
- 2021-02-16 CY CY20211100126T patent/CY1123837T1/el unknown
- 2021-06-11 JP JP2021097676A patent/JP2021178820A/ja active Pending
- 2021-11-01 AU AU2021261849A patent/AU2021261849A1/en not_active Abandoned
-
2022
- 2022-10-28 US US17/975,709 patent/US20230190749A1/en active Pending
- 2022-11-04 JP JP2022177278A patent/JP7404485B2/ja active Active
-
2023
- 2023-12-13 JP JP2023209972A patent/JP2024019526A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ756264A (en) | Treatment of brain cancer | |
| NZ602084A (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| MX2014004551A (es) | Dispersion solida. | |
| MX2015011818A (es) | Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico. | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| IN2012DN01453A (https=) | ||
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| WO2015054619A8 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
| IN2015DN00450A (https=) | ||
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| MD20160016A2 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| PH12014500967A1 (en) | A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| MX369518B (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
| MX339302B (es) | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina. | |
| TW201613577A (en) | Pharmaceutical combinations | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| NZ602807A (en) | 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor | |
| MX2014002817A (es) | Suspension oral. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 25 MAR 2023 BY THOMSON REUTERS Effective date: 20230118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2024 BY THOMSON REUTERS Effective date: 20230302 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2025 BY THOMSON REUTERS Effective date: 20240201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2026 BY THOMSON REUTERS Effective date: 20250203 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2027 BY THOMSON REUTERS Effective date: 20260202 |